Determinants of adjuvant oxaliplatin receipt among older stage II and III colorectal cancer patients

Cancer

Volumn 119, Issue 11, 2013, Pages 2038-2047

  Lund, Jennifer L ^a,b   Stürmer, Til ^a   Sanoff, Hanna K ^c   Brookhart, Alan ^a   Sandler, Robert S ^c   Warren, Joan L ^d  

^a IL   (United States)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

chemotherapy; colorectal cancer; Epidemiology and End Results Program; Medicare; Surveillance

Indexed keywords

ANTINEOPLASTIC AGENT; OXALIPLATIN;

ADJUVANT THERAPY; AGE; AGED; ALGORITHM; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; COHORT ANALYSIS; COLORECTAL CANCER; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DIVORCE; FEMALE; GEOGRAPHY; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MEDICARE; PATIENT INFORMATION; PHYSICIAN; POVERTY; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SEPARATED PERSON; UNITED STATES; WIDOWED PERSON;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; SEER PROGRAM; UNITED STATES;

EID: 84878014941     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27991     Document Type: Article

References (42)

1. Edler L, Heim ME, Quintero C, Brummer T, Queisser W,. Prognostic factors of advanced colorectal cancer patients. Eur J Cancer Clin Oncol. 1986; 22: 1231-1237.
2. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML,. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011; 103: 117-128.
3. Yabroff KR, Lund J, Kepka D, Mariotto A,. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev. 2011; 20: 2006-2014.
4. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008. National Cancer Institute: Bethesda, MD. http://seer.cancer.gov/csr/ 1975-2008/. Based on November 2010 SEER data submission, posted to the SEER Web site, 2011.
5. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007; 25: 3456-3461.
6. Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012; 307: 1383-1393.
7. Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011; 29: 11-16.
8. Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009; 27: 3117-3125.
9. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001; 345: 1091-1097.
10. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350: 2343-2351.
11. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009; 27: 3109-3116.
12. Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011; 29: 1465-1471.
13. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007; 25: 2198-2204.
14. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006; 24: 4085-4091.
15. Dotan E, Browner I, Hurria A, Denlinger C,. Challenges in the management of older patients with colon cancer. J Natl Compr Canc Netw. 2012; 10: 213-224.
16. Sanoff HK, Carpenter WR, Freburger J, et al. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: A Population-based analysis. Cancer. 2012; 118: 4309-4320.
17. Sanoff HK, Carpenter WR, Martin CF, et al. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst. 2012; 104: 211-227.
18. Sanoff HK, Carpenter WR, Sturmer T, et al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol. 2012; 30: 2624-2634.
19. Tournigand C, André T, Bonnetain F, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer Trial. J Clin Oncol. 2012; 30: 3353-3360.
20. Degner LF, Kristjanson LJ, Bowman D, et al. Information needs and decisional preferences in women with breast cancer. JAMA. 1997; 277: 1485-1492.
21. Yothers G, O'Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 Trial, including survival and subset analyses. J Clin Oncol. 2011; 29: 3768-3774.
22. Kemeny N, Braun DW Jr,. Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood cell count. Am J Med. 1983; 74: 786-794.
23. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF,. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40: IV-3 to IV-18.
24. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr,. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004; 291: 2441-2447.
25. National Cancer Institute. SEER-Medicare Data. http://healthservices. cancer.gov/seermedicare/overview/seermed-fact-sheet.pdf, May 2009. Accessed January 20, 2010. http://healthservices.cancer.gov/seermedicare/overview/ seermed-fact-sheet.pdf.
26. Centers for Medicare and Medicaid Services, Office of Information Services. Data from the 100 percent denominator file. Table 2.1-Medicare Enrollment. https://www.cms.gov/MedicareMedicaidStatSupp/08-2011.asp. Accessed August 20, 2011
27. Desch CE, Benson AB,3rd, Somerfield MR, et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2005; 23: 8512-8519.
28. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet. 1995; 345: 939-944.
29. Baldwin LM, Adamache W, Klabunde CN, Kenward K, Dahlman C, L Warren J,. Linking physician characteristics and medicare claims data: issues in data availability, quality, and measurement. Med Care. 2002; 40: IV-82 to IV-95.
30. Pollack LA, Adamache W, Eheman CR, Ryerson AB, Richardson LC,. Enhancement of identifying cancer specialists through the linkage of Medicare claims to additional sources of physician specialty. Health Serv Res. 2009; 44: 562-576.
31. Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002; 20: 485-493.
32. Wolmark N, Rockette H, Wickerham DL, et al. Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol. 1990; 8: 1466-1475.
33. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002; 40: IV-55 to IV-61.
34. Harmon JW, Tang DG, Gordon TA, et al. Hospital volume can serve as a surrogate for surgeon volume for achieving excellent outcomes in colorectal resection. Ann Surg. 1999; 230: 404-411.
35. Du XL, Fang S, Vernon SW, et al. Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer. Cancer. 2007; 110: 660-669.
36. Mandelblatt JS, Kerner JF, Hadley J, et al. Variations in breast carcinoma treatment in older medicare beneficiaries: is it black or white. Cancer. 2002; 95: 1401-1414.
37. Klabunde CN, Potosky AL, Legler JM, Warren JL,. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 1258-1267.
38. Miglioretti DL, Heagerty PJ,. Marginal modeling of nonnested multilevel data using standard software. Am J Epidemiol. 2007; 165: 453-463.
39. Carpenter WR, Meyer AM, Wu Y, et al. Translating research into practice: the role of provider-based research networks in the diffusion of an evidence-based colon cancer treatment innovation. Med Care. 2012; 50: 737-748.
40. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004; 22: 1797-1806.
41. Gupta SK, Lamont EB,. Patterns of presentation, diagnosis, and treatment in older patients with colon cancer and comorbid dementia. J Am Geriatr Soc. 2004; 52: 1681-1687.
42. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005; 97: 1407-1427.